Used in pharmaceutical research as a potent and selective inhibitor of the enzyme diacylglycerol O-acyltransferase 1 (DGAT-1), which plays a key role in triglyceride synthesis. This compound is investigated for its potential in treating metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) by modulating fat absorption and storage. It has shown efficacy in preclinical models in reducing body weight gain and improving insulin sensitivity. Its structure allows for high binding affinity and selectivity, making it a valuable tool compound in metabolic disease drug development.